HealthQuill Eli Lilly
The WHO says close to 18 million people die due to cardiovascular disease every year out of which maximum deaths are due to SCA. Heart attacks occur when there is a blockage in one or more of the arteries to the heart, preventing the heart from receiving enough oxygen-rich blood.
Pharma

Eli Lilly’s pill for genetic high cholesterol cuts risk by 86% in trial 2

HQ Team November 19, 2024: Eli Lilly announced promising results from its Phase 2 clinical trial of muvalaplin, an oral medication designed to.

Read More
obesity
Health

Lilly’s trial results for treating obesity and pre-diabetes are promising

HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.
Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

Read More
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor to treat inflammatory bowel disease.
Drugs Health Pharma

Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies

Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.

Read More
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.
Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

Read More
Semaglutide based weightloss drugs tied to increased suicide risk in a new study
Drugs Health Pharma

Eli Lilly’s LillyDirect offers direct access to obesity medication

HQ team January 6, 2024: Eli Lilly, the pharmaceutical company will now be selling its weightless drug directly to the consumer via its.

Read More
Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood cancer drug Jaypirca.
Drugs Health Pharma

Eli Lilly’s drug gets second FDA nod for treating blood cancer in adults

HQ Team December 4, 2023: Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More